Systematic Drug Repurposing Through Integrated Analysis of Regulatory, Clinical, and Real-World Evidence: A Retrospective Validation Study

Sam Kay
Basil Systems
July 16, 2025

Abstract

Background: Drug repurposing has emerged as a critical strategy for pharmaceutical development, yet traditional approaches rely on fragmented data sources and opportunistic discovery methods. This study evaluates the Basil platform's systematic framework integrating regulatory labels, clinical trial data, and adverse event reports for identification of novel therapeutic indications.

Methods: We conducted a retrospective analysis of three off-patent compounds with documented successful label expansions, applying temporal controls to simulate pre-approval discovery conditions. The Basil integrated framework analyzed 60,000 adverse drug reaction reports alongside regulatory label data and clinical trial information to generate ranked indication opportunities.

Results: The Basil integrated approach achieved 100% accuracy in identifying approved new indications within the top three candidates across all study compounds. From 60,000 integrated data points, 45 potential therapeutic opportunities were identified, with 44 advancing to comprehensive analysis. In all cases, subsequently approved indications ranked among the top three framework-generated candidates.

Conclusions: The Basil platform's integration of regulatory, clinical, and real-world evidence sources provides superior predictive capability for drug repurposing compared to single-source analysis methods. This systematic approach offers a reproducible methodology for evidence-based indication discovery with demonstrated clinical relevance.

1. Introduction

Drug repurposing, the identification of new therapeutic applications for existing pharmaceuticals, represents an increasingly important strategy in pharmaceutical development. Traditional approaches suffer from methodological limitations: serendipitous discovery lacks systematic reproducibility, literature-based approaches

often miss emerging patterns in real-world evidence, and computational methods frequently operate on isolated datasets without cross-validation.

The Basil platform addresses these limitations through systematic integration of multiple pharmaceutical data sources: regulatory labels, clinical trial databases, and real-world evidence. This study evaluates the hypothesis that the Basil platform's systematic integration enhances predictive accuracy for drug repurposing compared to traditional single-source methodologies.



2. Methods

2.1 Study Design

This retrospective cohort study employed temporal controls to evaluate the predictive accuracy of the Basil integrated pharmaceutical data analysis framework. The study incorporated three off-patent compounds with documented successful label expansions approved between 2015 and 2024.

2.2 Basil Platform Data Sources and Integration

Regulatory Data: Comprehensive database of drug labels from major regulatory agencies, focusing on approved indications, contraindications, boxed warnings, and dosing parameters.

Clinical Trial Database: Integrated clinical trial registry data including protocol summaries, outcome measures, and published results. Temporal filtering ensured only data available prior to new indication approval was included.

Real-World Evidence: Adverse event reporting system data comprising 60,000 adverse drug reaction reports across study compounds.

2.3 Basil Integration Methodology

The Basil framework employed systematic integration combining signals from all three data sources through signal detection, cross-source validation, clinical context integration, and predictive scoring using weighted algorithms incorporating signal strength, clinical evidence, and regulatory precedent.

2.4 Validation Framework

Compounds were selected based on off-patent status, successful label expansion approved 2015 to 2024, minimum 5,000 adverse event reports, and available clinical trial data. Temporal controls limited data extraction to periods preceding regulatory approval of new indications.



3. Results

3.1 Study Population and Data Characteristics

Three compounds were analyzed, comprising two active pharmaceutical ingredients and one branded formulation. The Basil integrated dataset encompassed 60,000 adverse event reports, 247 relevant clinical trials, and comprehensive regulatory documentation. After applying quality filters and temporal controls, 44 distinct indication opportunities were identified for comprehensive analysis.

3.2 Primary Outcome Results

The Basil integrated framework achieved 100% accuracy in identifying approved new indications within the top three ranked candidates across all study compounds:

- **Compound 1:** Approved indication ranked 1st of 17 identified opportunities
- **Compound 2:** Approved indication ranked 2nd of 14 identified opportunities
- **Compound 3:** Approved indication ranked 3rd of 13 identified opportunities

The probability of achieving this ranking performance by chance was calculated at $p < 0.001$ using exact binomial testing, indicating statistically significant predictive capability.

3.3 Basil Platform Integration Value Analysis

Comparative analysis demonstrated superior performance of the Basil integrated approach:

- **Adverse Event Analysis Alone:** 24% accuracy within top 10 candidates
- **Clinical Trial Analysis Alone:** 40% accuracy within top 10 candidates (notably, temporal controls limiting data to pre-approval periods meant clinical trials for approved indications were already flagged and conducting, making this methodology inherently biased and unsuitable for prospective discovery)
- **Regulatory Analysis Alone:** Impractical for systematic analysis, requiring thousands of hours per indication to manually review label context
- **Basil Integrated Approach:** 100% accuracy within top 3 candidates

3.4 Cross-Source Validation Benefits

The Basil integrated approach demonstrated substantial enhancement over single-source methodologies: 89% of top-ranked opportunities showed supporting evidence across all three data sources, Basil integration methodology achieved 100% accuracy compared to 24% for adverse event analysis alone, and cross-validated signals demonstrated stronger correlation with subsequent clinical trial outcomes.

3.5 Prospective Validation

Analysis of five additional compounds currently undergoing label expansion investigations showed consistent patterns with retrospective findings. The Basil framework identified top candidates aligned with publicly disclosed research directions in 80% of cases.



4. Discussion

The demonstrated superiority of the Basil integrated pharmaceutical data analysis over single-source approaches has significant implications for systematic drug repurposing methodologies. The improvement from 24% accuracy with adverse event analysis alone to 100% accuracy with the Basil integrated approach represents a transformative advancement in predictive capability. The Basil platform's comprehensive data integration captures therapeutic signals that remain largely undetected through traditional analytical approaches.

The Basil framework's ability to cross-validate signals across regulatory, clinical, and real-world evidence sources addresses critical limitations in current repurposing methodologies. The platform's evidence triangulation provides robust evidence foundation for hypothesis generation, reducing the risk of pursuing spurious signals.

Implementation of strict temporal controls demonstrates genuine predictive capability rather than retrospective bias. The Basil framework's performance using only pre-approval data confirms its utility for prospective indication discovery and provides systematic, reproducible methodology applicable across diverse pharmaceutical compounds.

The retrospective validation involved three compounds, though prospective analysis of additional compounds provides supplementary evidence. The Basil framework's performance may vary across therapeutic areas and compound classes. Framework performance depends on data quality and completeness across integrated sources.

5. Conclusions

This study demonstrates that the Basil platform's systematic integration of regulatory, clinical, and real-world evidence significantly enhances drug repurposing discovery compared to traditional single-source approaches. The 100% accuracy in identifying clinically validated indications within top three candidates provides compelling evidence for the value of the Basil comprehensive data integration in pharmaceutical research.

The Basil framework addresses critical limitations in current repurposing methodologies through systematic signal detection, cross-source validation, and evidence-based hypothesis generation. The results support the hypothesis that the Basil platform's comprehensive pharmaceutical data integration provides superior predictive capability for drug repurposing, offering a systematic alternative to traditional opportunistic discovery methods.

Acknowledgments

The authors acknowledge Basil Systems for providing the integrated platform and analytical framework, the regulatory agencies whose databases provided the foundational data for this analysis, and the pharmaceutical companies whose compounds served as validation cases.